Other
Phase IB
0
Pipeline Programs↗
11
Active Trials↗
14
Companies Involved↗
Phase IB is an early-stage landscape with 0 programs across 14 companies. The most active players are Novartis, Nanjing RegeneCore Biotech Co., Ltd., Shanghai HEP Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
25
clinical trials
Completed10 · 40%
Recruiting8 · 32%
Terminated2 · 8%
Not yet recruiting2 · 8%
Unknown status1 · 4%
Withdrawn1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
25 trials
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05953350·29 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)